featured
Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Chest
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine Reduces Exacerbation Rate and Risk in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
Chest 2024 Aug 26;[EPub Ahead of Print], FC Sciurba, SA Christenson, T Rheault, T Bengtsson, K Rickard, IZ BarjaktarevicFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.